Phase I/II study of bisantrene in childhood cancer: A report from the childrens cancer study group

✍ Scribed by Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: English
• Weight: 328 KB
• Volume: 16
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950160508

✦ Synopsis

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respectively. The dose limiting toxicities were hepatic and hematologic. One patient with ALL achieved a complete remission and partial responses were observed in three patients with soft-tissue sarcomas. The data indicate that bisantrene, at the doses and schedule used in this study, has limited antitumor activity in pretreated children with cancer.